MedAvail Holdings, Inc. (NASDAQ:MDVL) Q4 2021 Earnings Conference Call March 24, 2022 4:30 PM ET
Company Participants
Caroline Paul – MD, The Gilmartin Group, IR
Mark Doerr – CEO
Ramona Seabaugh – CFO
Conference Call Participants
Brooks O’Neil – Lake Street Capital Markets
Operator
Good afternoon. And welcome to MedAvail’s 2021 Fourth Quarter Earnings Conference Call. My name is Sam, and I will be your moderator for today’s call. All lines will be muted during the presentation portion of the call, with an opportunity for question-and-answer session. [Operator Instructions].
At this time, I’d now like to turn the call over to our host, Caroline Paul, Investor Relations. Caroline, please proceed.
Caroline Paul
Thank you. And thank you all for participating in today’s call. Joining me are Mark Doerr, Chief Executive Officer; and Ramona Seabaugh, Chief Financial Officer.
Earlier today, MedAvail Holdings, Inc., referred to as MedAvail or the company, released financial results for the fourth quarter and full year ended December 31, 2021. A copy of the press release is available on the company’s website.
Before we begin, I’d like to remind you that management will make statements during this call, including statements or responses in addressing your questions that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call are in response to your questions that relate to expectations or predictions of future events, results or performance or similar statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, the impact of COVID-19 and the military action launched by Russian forces in Ukraine on our business and prospects for recovery, expense management, expectations for hiring, growth in our organization and reimbursement, market opportunity and expansion and guidance for revenue, gross margin and operating expenses in 2022 are based upon our current estimates and various assumptions.
Any forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements and do not guarantee future performance. Accordingly, you should not place undue reliance on these statements and should not rely on them in making an investment decision without considering the risks associated with such statements.
For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section in our most recent periodic reports, including our annual report on Form 10-K and our quarterly report on Form 10-Q filed with the Securities and Exchange Commission.
In addition, as part of this earnings call, the company’s management team is providing additional financial information related to adjusted EBITDA. The company calculates adjusted EBITDA, a non-GAAP financial measure, by including interest, expense, depreciation and amortization, stock-based compensation and excluding non-recurring expenses and other income to net loss.
The company has included adjusted EBITDA in this earnings call because it is a key measure used by the company’s management and board of directors to evaluate and compare the company’s financial and operational performance over multiple periods identifying trends affecting the company’s business, formulating business plans and making strategic decisions. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain non-recurring variable charges.
In addition, the company believes that providing each of EBITDA and adjusted EBITDA, together with a reconciliation of net loss to each such measure, helps investors make comparisons between MedAvail and other companies that may have different capital structures, different tax rates and/or different forms of employee compensation.
Adjusted EBITDA should be viewed as measures of operating performance that are supplement to and not substitute for operating loss, net loss and other U.S. GAAP measures of income and loss. Non-GAAP financial measures used by the company may be calculated differently from and, therefore, may not be comparable to similarly titled measures used by other companies.
This conference call contains time sensitive information, and is accurate only as of the live broadcast today, March 24, 2022. MedAvail disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements whether because of new information, future events or otherwise.
And with that, I will turn the call over to Mark.
Mark Doerr
Thank you, Caroline. Good afternoon, everyone. And thank you for joining us. I’m very pleased to be participating in my first earnings call as CEO of MedAvail. It is a privilege to be leading this company. And I thank the Board for this opportunity. By way of background, I’ve spent my entire career in pharmacy, starting as a pharmacist and working across this industry in various other capacities, including leading national and regional retail pharmacy chains.
Most recently, I was CEO of eRx Network until its acquisition by Change Healthcare in 2020. Under my three-year tenure, the company’s revenue and EBITDA increased in each year before the acquisition. I believe that pharmacy is a big business with a significant opportunity for novel models to improve efficiency and patient outcomes while achieving discipline with respect to cost and quality. And I strongly believe that our new team at MedAvail is uniquely poised to address this opportunity.
I was attracted to MedAvail for two reasons. First, I was impressed by MedAvail’s differentiated technology platform, our MedCenter and its supporting system that enables our on-site pharmacy at the point of care in a cost-effective way. Second, I believe in the opportunities that our solutions provide given how strongly positioned we are to solve a multifaceted problem that challenges pharmacy services today. There’s a clear need for solutions to address the gaps faced by both retail pharmacies and at-risk value-based medical providers.
Retail pharmacies struggle with labor shortages and higher costs, resulting in reduced operating hours and compromised service levels, which effectively limit patient access to their medications. These factors contribute to reduced patient satisfaction and lower medication adherence. Poor Medicaid adherence tends to result in suboptimal patient outcomes and impact the Star Ratings for at-risk providers, which in turn, affects the reimbursement levels provided by TMS.
Moreover, many medical providers don’t have adequate connectivity to the many pharmacists that their patients utilize, constraining their ability to gain insights on medication adherence for their patients, which limits their ability to impact patient outcomes.
To address these challenges head on, we deliver flexible and comprehensive solutions to our partners with a model that I believe is increasingly essential for value based care delivery. At the core of our offering is our proprietary MedCenter platform through which we deliver cost effective pharmacy prescription dispensing and advice at the point of care to provide better and more convenient patient access and drive improved outcomes and provider satisfaction and reimbursement.
Since joining MedAvail, my confidence in our business and the opportunities for it has grown. There is a tremendous market opportunity to be realized with our solutions, and we have a definitive road map intended to meet this rising demand. I also believe that we have a clear pathway to deliver profitable growth in the business.
To that end, as some of you already know, our business model has two segments: Pharmacy Technology and Retail Pharmacy Services. And I would like to walk you through what we are doing with each segment.
Starting with the Pharmacy Technology. This area of our business represents the most significant opportunity for MedAvail and is a large part of our path towards profitability. We sell our hardware and importantly, license our software and systems to support it and provide maintenance for the platform, which is intended to create a highly profitable recurring revenue stream. Our MedCenters are currently being operated by large scalable partners such as Sam’s Club, HCA and Texas Health Resources, a mix of retail and health system pharmacies, which we believe are both very viable channels for our expansion.
We are also pleased to have recently partnered with the University of Florida. We will provide an initial three MedCenters to be deployed in their various campus facilities and have the opportunity to expand this relationship to include a variety of additional sites.
A critical component to Pharmacy Technology segment is the MedCenter interface with the pharmacy management system. As part of our focus to drive growth in this business, we have received approval for our app to be in the Epic App Orchard, which will allow us to integrate into the Epic platform through Epic Willow, its outpatient pharmacy management system. This capability is intended to allow us to add site deployments with the many health system customers who use Epic and will significantly reduce the time from signing a deal with MedAvail to deployment of our platform.
Importantly, we anticipate that this integration work will open the market of installed Epic users to MedAvail as prospects for our Pharmacy Technology. Currently, there are approximately 350 integrated delivery networks using the Epic pharmacy software in the United States, representing thousands of potential sites for our MedCenter. We expect this integration through Epic Willow to be completed in the second quarter of 2022.
To support the growth opportunity that we see with the Pharmacy Technology, we are making investments and strengthening our team. We recently added new sales leadership and support in this segment and are continuing to develop our team to drive product innovation and sales.
Turning to Retail Pharmacy Services and SpotRx, our highly scalable hub-and-spoke pharmacy model. We deliver a unique value proposition to our clinic partners with our embedded SpotRx Pharmacy. And we are focused on clinic operators that service the Medicare market with large and growing networks to maximize the potential of our land and expand strategy. Our clinic partners primarily operate in a value-based care model and are looking for a pharmacy partner that can fully complement their patient care and reimbursement models.
We leverage data to drive patient adoption, monitor performance to adapt and optimize our offering to each clinic location, helping to identify and focus on high value patients for our partners. Each of our SpotRx service areas operate a centralized pharmacy hub designed for easy and rapid scaling. Once we establish a hub pharmacy in a market, we have historically been able to quickly deploy additional MedCenters to surrounding clinic providers.
To date, we have seven hub pharmacies across our key target states. Our most recent hub pharmacy opened in Orlando, Florida in June of 2021 and notably, now services over 30 dispensing units across this market.
A number of these SpotRx locations are associated with our partnership with IMA and is a great example of the land and expand strategy at work. Through our partnership with IMA, we opened 4 initial SpotRx locations at IMA sites in late 2020. And recently, we announced the expansion of our partnership to include all IMA medical centers across Central Florida. We opened five additional SpotRx locations at IMA sites late in 2021 and have deployed or began installation for an additional 11 SpotRx locations this year.
This rapid growth and expansion of the IMA network demonstrate how quickly we become an integral part of a medical center through our strong value proposition with SpotRx.
We are also aiming to leverage our expansion with clinic partners and grow alongside them as they continue to build out their networks. Most recently, we expanded our partnership with Oak Street Health with an additional two SpotRx installations added in Michigan in 2021 and have agreed with Oak Street Health to deploy in Arizona with three initial contracted locations, a great example of how we can expand in two of our key target markets with existing partners to drive enhanced utilization of our existing hub pharmacy.
Oak Street Health operates more than 100 comprehensive primary care centers across 19 states for senior adults.
We are pleased to announce that we are also expanding our partnership with Cano Health. We had initially contracted with Cano to open four SpotRx locations in Orlando area and contracted for an additional four locations in the Greater Los Angeles area in the fourth quarter of 2021. I am pleased to report that we recently contracted for an additional nine sites in the Tampa, Florida area. We are looking forward to leveraging our new Tampa pharmacy hub for this opportunity.
With these new deployments and expanding partnerships, we are continuing to build the foundation for scalable and sustainable revenue growth with large and growing value based care providers. As we think about this growth, we look to deployment as a leading indicator of the strength in our momentum. We finished 2021 with 46 new deployments and momentum in the business.
To provide some more context around deployment and how we are thinking about our growth, we want to introduce a new metric, dispensing MedCenters. Ramona will walk you through the details around our metrics. But at the end of 2021, we had 81 net cumulative deployments to date, 68 of which are dispensing MedCenters, representing 76% and 79% growth over the prior year respectively.
Importantly, we have also initiated internal measures intended to ramp up our deployments efficiently and effectively so that our partners can quickly realize the value proposition with SpotRx. Underlying all of this growth, we are heavily focused on the profitability of our business. We have programs underway in 4 areas to achieve improved margin, driving prescription volumes, optimizing our prescription mix, reducing cost of goods and improving reimbursement.
We have set forth specific initiatives with respect to each of these areas. As a preview into one of these initiatives, we are deploying a comprehensive procurement strategy from sourcing products to drive utilization and the appropriate mix of medications using data and our pharmacy management system intended to ensure the highest available reimbursement for the prescription.
We are also enhancing our leadership team, bringing in new talent and skills to drive these efforts, including most recently, the addition of an industry leader in data utilization and analytics to optimize and accelerate data exchange with our clinic partners and enable improved efficiencies for the benefit of our patient and clinic partners. We intend to use patient appointment data and prescriber data to optimize the utilization of our MedCenters, which helps drive first fill adherence and patient satisfaction with the convenience of on-site dispensing.
We exited the year with strong results. In the fourth quarter, net revenue was $7.3 million, representing 26% sequential revenue growth from the third quarter of 2021 and 135% growth year-over-year. Retail Pharmacy Services generated $6.8 million in revenue for the fourth quarter of 2021, representing 170% growth over the same period in 2020, while Pharmacy Technology revenues declined 24% year-over-year in the fourth quarter of 2021 to approximately $434,000.
Pharmacy Technology revenue can be variable from quarter-to-quarter due in large part to customer purchasing patterns associated with enterprise level capital sales. We are intently focused on driving revenue in this segment, as we noted earlier.
Looking ahead to the first quarter, we expect approximately $8.8 million in total revenue, representing 21% growth relative to the fourth quarter of 2021 and more than double our net sales compared to the same period in 2021. We also expect to see adjusted gross margin improvement in the first quarter of 2022 compared to the fourth quarter of 2021.
In summary, while I’m still in the early weeks of leading our MedAvail team, we are enthusiastic about the differentiated value proposition and competitive advantage of our pharmacy solutions and the strong momentum we continue to deliver with our business.
As you would expect, I’m spending my time on some immediate practical needs and on ensuring that we have the people and skills in place to drive the business forward. With this well underway as we continue to execute and deliver, I’m excited to spend time with this revitalized team to look beyond our immediate significant opportunities and update, refine and validate our strategy and plan for the future. We are also working to secure additional financing to move our various initiatives forward. I look forward to talking more about this in the months ahead.
In the more immediate term, as we work to refine our operational initiatives, I am confident that we are strongly positioned with our expansion plans underway and more opportunities presenting themselves in our existing business areas while we focus on delivering profitable and sustainable growth in the future.
With that, I’ll now turn the call over to Ramona to provide a review of our fourth quarter financial results.
Ramona Seabaugh
Thank you, Mark. Turning to our fourth quarter results. Net revenue for the three months ending December 31, 2021, was $7.3 million, a 135% increase from $3.1 million in the same period of the prior year. This was aided by 170% increase in Retail Pharmacy Services revenue. As we’ve indicated in the past, Pharmacy Technology revenue can be variable from quarter-to-quarter due in large part to customer purchasing patterns associated with enterprise level capital sales.
As Mark mentioned, we deployed 46 new MedCenters in 2021. At the end of 2021, we had 81 net cumulative deployments to date and 68 dispensing units, representing 76% and 79% growth over the prior year, respectively.
I want to take a moment now to define these metrics. We have excluded the previously discussed non-revenue generating sites from our deployment metrics such as pilot, decommission equipment and demo site. We define dispensing unit as the sites that are live, that is have payer network acceptance, pharmacy board approvals and trained clinical staff or clinical account managers. Moreover, we work closely with [indiscernible] pharmacy and our clinic partners to reduce the time to progress from deployment to becoming dispensing units, which generally takes 4 to 12 weeks.
Gross margin for the fourth quarter of 2021 was negative 5% as compared to negative 7.9% in the fourth quarter of 2020. The negative margins were a result of inventory write downs of $626,000 and $352,000 in the fourth quarter 2021 and 2020, respectively. The inventory write downs in the fourth quarter of 2021 was specific to the M5 model of our MedCenter within the Pharmacy Technology segment and is not related to the M4 models currently being sold to third parties and deployed within SpotRx. We now carry our M5 inventory at zero, given that we and our customers are focused on the M4 models. Without inventory write downs in both the fourth quarters of 2021 and 2020, gross margin was 3.6% and 3.4%, respectively.
Total operating expenses for the fourth quarter of 2021 were $12 million, a 5% increase from $11.4 million in the fourth quarter of 2020. Our operating costs have increased primarily as a result of our pharmacy operations and clinical account manager labor costs in support of additional MedCenter deployment.
Notably, our general and administrative costs have stabilized quarter-over-quarter.
Adjusted EBITDA, which we calculate by adding back interest expense, depreciation and amortization, stock-based compensation and exclude non-recurring expenses and other income to net loss, was a loss of $10.9 million in the fourth quarter of 2021 compared to a loss of $8.9 million in the fourth quarter of 2020, reflecting growth in place.
We ended the fourth quarter of 2021 with $19.7 million of cash and cash equivalents. We have a number of options we’re actively pursuing to extend our runway.
Turning to our outlook. For the first quarter of 2022, we expect approximately $8.8 million in total revenue. We expect 25 to 30 net dispensing units in 2022.
Regarding our gross margin outlook, we remain focused on improving our adjusted gross margins and operating costs throughout the balance of 2022.
And with that, I’ll turn the call back over to Mark for closing comments.
Mark Doerr
Thank you, Ramona. Thank you for joining the call today. We look forward to updating you on our progress as we continue to execute across our strategic initiatives and drive profitable growth.
With that, we will now open it up to questions. Operator?
Question-and-Answer Session
Operator
Thank you, Mark. We will now begin the Q&A session. [Operator Instructions] Our first question is from Charles Rhyee of Cowen. Charles Rhyee?
Unidentified Analyst
Hey, guys. This is actually James on for Charles. Previously, it’s been noted that on average, each deployment generates about $1 million in revenue at full run rate. Can you give us an update on this revenue target? Are MedCenters a year or more — deployed a year or more ago generating about $1 million in revenue on average? Maybe you can give us some color on what revenue looks like on like a median basis, 75 percentile basis for those that have been deployed over a year ago?
Ramona Seabaugh
Sure. Hi, James. This is Ramona. And in the past, we have used net deployments as a leading indicator. And now we’re focused on the number of dispensing sites as those are the ones generating revenue and were associated with that $1 million target.
As we look historically at our mature sites. We’re seeing that in year one, we’re typically finding $200,000 to $250,000 in annual revenue. In years two, rate $500,000 to $600,000. By year three, we’re in $700,000 to $800,000. As of the end of last year, we have 68% units that were generating revenue. We expected as Mark said, an additional 25 to 30 units in fiscal year ’22. So as we look to how we’re qualifying sites now groupies [ph] in the past, we’re seeing and believing that the new sites are performing better than the median rate. So we’re leaning towards the 75th percentile to be our target, which would start seeing that $1 million come in year three.
We feel comfortable with the goal of $1 million for the site set maturity. But I want people to understand that we have impacts to our revenue ramp such as like timing for a new or existing clinic. If it’s a new clinic, it’s going to take longer for it to ramp up. We call this de novo clinics. We also — if we’re entering into a new market, it could take us time to get accepted into insurance plan. So that could take a few weeks to get into all the plans. I think we said in the past four to 12 weeks to be fully ramped up.
We can also have impacts to our volume through clinic staffing and patient penetration rate. And then finally, like the average sales price is impacted by our payer mixes and the types of prescriptions we’re filling.
So we expect to continually improve the ramping for our revenue with the new clinics we’re bringing on and the selection process that we have in place. And we’re seeing that our clinics are generating some those, plants that are generating over $1 million.
Mark, maybe can you add to what we’re doing that kind of moving the median rate up towards the 75th percentile?
Mark Doerr
Sure. Thanks. I think the key to what we’re seeing with the most recent clinics are our qualification process. So we’re really selecting the right clinics that we go into, but we’re also doing a much better job as we go live and really around our training, both for our clinical account managers as well as for the provider themselves so they feel comfortable in recommending our services.
And then the last thing is we’re using data more effectively once we’re in market to both monitor the performance of the clinic itself and also adapt to the clinic such as the prescribing patterns, making sure that we have the right inventory in the MedCenter to capture the first fill dispensing.
Ramona Seabaugh
Does that answer your question?
Unidentified Analyst
Okay. Great. Yeah, that’s very helpful. In the prepared remarks, I think you had mentioned that you’re looking to ramp up sites more efficiently. Can you maybe give us some color on what you’re doing to maybe accelerate or enhance this ramping process?
Mark Doerr
Yeah. I think I’d go back to just the comments I just made similarly. I think we’re really doing a better job in selecting those sites, right? And then the other thing is it’s really the end market performance. And again, it’s now using that data. We’re starting to get appointment data so we know when patients are coming in to make sure that we’re focused on those high value patients for our partners as well as, like I said, making sure we have the inventory and stock to dispense prescription while they’re in the clinic at the point of care.
Unidentified Analyst
Okay. I mean, we appreciate you providing first quarter 2022 revenue guidance. But is there any color you could give on, I guess, revenue growth for the entire year or at least the key puts and takes we should be considering? Maybe some details on like the progression of the 25 to 30 net dispensing sites would be helpful.
Mark Doerr
Yeah. We’re not providing sort of the full year revenue guidance at this time. I think that’s why we went and want to provide the information on the 25 to 30 dispensing units for the year, given that’s how they drive — how we derive revenue. And that’s very similar to last year’s sort of overall deployment, right, would get us from 68 to roughly 95 to 100 total dispensing units.
And I would say we’re continuing to assess and I’m working with the Board, provide guidance, revenue guidance in a future update.
Unidentified Analyst
Okay. And similarly, I guess, sequential improvement expected in 1Q ’22 on an adjusted gross margin basis. Should we think that margins sequentially improve throughout the course of the year? I know you’re not giving full year guidance, but anything on that front would be helpful.
Ramona Seabaugh
Yeah. So we finished the full year about 1.4% unadjusted with 4.3% adjusted. We do expect that those will continue to improve quarter-over-quarter. We’re targeting between 8% and 9% in adjusted gross margin within the next four to six quarters with our long-term goal being right around 15%, aligned with the industry average.
We have a lot of initiatives that we’re putting in place in like four key buckets, utilization, mix, cost of goods sold and reimbursement. And Mark, do you want to add some things that the team is working on?
Mark Doerr
I think you covered it really well. When you start to think about it and I said we’re putting in sort of a full procurement strategy around how we buy at the lowest cost, but that we actually followed through making sure that our pharmacists are purchasing those items, dispensing those items and looking at how that rolls into the reimbursement that’s coming in.
I think the other thing we’re very focused on is generic substitution. And — because generics typically will carry a higher gross margin, and that will help us achieve that 8% to 9% that Ramona spoke about.
The last thing I would say on the mix is we do want to continue to drive technology sales, which has a much higher gross margin associated with it. And we’d like to get that to be a larger portion of our total revenue.
Unidentified Analyst
Okay. That’s a good segue into my last question on Pharmacy Technology, which seems to be a greater focus. I guess, what percent of total revenue do you think Pharmacy Technology ultimately could represent in the future? And maybe you could talk about what the sales pipeline in Pharmacy Technology looks like now, given the new sales leadership that you just hired?
Mark Doerr
Yeah. I think previously, the company has talked about targeting 20% for the technology revenue segment. I’m continuing to do an assessment on that. But I think that, that’s probably a realistic target for us as we go forward.
When I think about the sales pipeline. I mean, for 2021 this year, we’re going to expect the revenues to be flat. Our — for 2022, we expect the revenues to be flat to 2021. But the pipeline is really going to be strengthened as we complete our Epic integration. And Epic integration is sort of twofold. One, we need to get our MedCenter app in the Epic App Orchard, and we did just get approval in the month of March for our app to be in the Epic App Orchard. So that was the first step.
The second step is we’re working with our first Epic partner to complete an integration. And that should be done by the beginning of Q3, which will expand the number of outlets that we can go after. Specifically, it opens up about 350 health systems to us, which could represent thousands of placements.
And I also would say, we have an integration with the McKesson enterprise system, which represents thousands of potential placements within retail. So we see both retail and health systems being viable channels for expansion as we move forward.
Unidentified Analyst
Okay. Thank you for all color.
Mark Doerr
Thank you, James.
Ramona Seabaugh
Thanks, James.
Operator
Thank you, James. Our next question is from Brooks O’Neil of Lake Street Capital Markets. Brooks, you may proceed.
Brooks O’Neil
Thank you. Good afternoon, Mark and Ramona. I have a few questions, I guess. So just following on with the last question on Pharmacy Tech, do those — do you expect those deployments to include a MedCenter unit ultimately? Or is it 100% of software sale?
Mark Doerr
Brooks, it’s a good question. Always we’ll have the hardware associated with it. Because the MedCenter is the platform for the dispensing. And then the software, as you recognize, we license the software with the MedCenter, and then we bill monthly for software and maintenance. So there’ll always be a hardware component.
Brooks O’Neil
Okay. Cool. And then I’m just curious, were there any incremental terminations or reductions in deployment here either towards the end of the year or early in 2022?
Mark Doerr
No, there were not.
Brooks O’Neil
Okay. So would you say those units that are out in the field, you’re either optimistic or you’re pleased with the performance?
Mark Doerr
Yeah. We’re continuing to assess the performance of all the MedCenters inside of the SpotRx hub pharmacies that we run. And I would say that we are pleased with the MedCenters that are out in the field today, but we’ll continue to monitor performance to ensure that we’re maximizing the return from each MedCenter and each clinic.
Brooks O’Neil
Sure. That’s great. So let me ask just one more. I’m curious what I hear in general, obviously, there are regional variations, but I hear that the impact of COVID has continued to decline, that there was quite a bit of impact in January but less in February and even less in March in most areas. And I’m curious if you can comment at all about how that’s affected the utilization of the MedCenter pharmacy, and I’m thinking about it in terms of patients. Was there more in-clinic utilization? Was there more delivery, home delivery? Thinking about it in terms of the response you saw from the physicians that had access to MedCenters units. Was there any big change that you saw through the quarter? And do you expect any change as we move into the middle part of 2022?
Mark Doerr
Brooks, it’s a good question. I would say we didn’t see a substantial change in sort of the existing MedCenters from a utilization called the first fill dispensing versus delivery to home. I will say as we brought Florida online right in the last six months and they’ve become a significant portion of our dispensing MedCenters. We’ve actually seen an increase in the utilization of the MedCenter itself comparatively correct [ph]. So that’s been a really — a key focus for us. And we want to continue to optimize the MedCenter. And that’s utilizing the data from the prescribers and from our clinic partners to make sure we have the right inventory in the MedCenters.
Brooks O’Neil
Yeah, that’s great. Thanks a lot. And I’m optimistic about better year for you in 2022.
Mark Doerr
We appreciate that, Brooks. Thank you.
Ramona Seabaugh
Thank you, Brooks.
Operator
Thank you, Brooks. And there are no further questions waiting at this time. So I’ll hand the call back over to Mark for any closing remarks.
Mark Doerr
Just want to say thank you, everyone. Stay safe, and have a great night.
Operator
That concludes the MedAvail’s 2021 fourth quarter earnings conference call. Thank you all for your participation. You may now disconnect your lines.
Be the first to comment